Sino Medical's profit surge and overseas approvals drive the story
First-half profit jumps on coronary and neuro product sales Sino Medical said first-half 2026 net profit should rise about 264% to 50.3 million yuan, as its coronary products sold more and new neuro products grew strongly, with revenue up about 27% and costs controlled. That profit growth is the main force pushing the stock up.
This is the core earnings driver behind the period's move.
Interim report confirms the profit jump and healthy cash flow The actual interim report matched the forecast: 305 million yuan revenue, 50.3 million yuan net profit, and 94 million yuan of cash coming in from operations. A low debt ratio and 70% gross margin show the business is profitable and not stretched, supporting the shares.
It confirms the earnings surprise with real numbers and cash flow.
Overseas approvals open new markets for heart devices Sino Medical won registration for its coronary balloon catheter in Vietnam and Colombia, letting it sell these heart products in those countries. Each approval is a small but real step in overseas expansion, adding future sales that support the stock price.
New market approvals are a fresh growth path for the company.
H-share listing plan and Paraguay stent approval add capital and reach Sino Medical is filing to issue H-shares in Hong Kong, expected to finish early next year, which could raise new money. Its HT Supreme drug-eluting stent also won approval in Paraguay. Both broaden funding and sales, though the H-share plan is still pending.
It shows a new funding route and another overseas market.